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   TIMELINES: REFERRAL TO DIAGNOSIS AND TREATMENT 
Referral to First Seen by Urologist and TURB 
 59% of patients were seen by a urologist within 4 weeks of referral while 27% waited over 6 weeks. 
 The overall duration from referral received to first seen by urologist was longer for patients presenting in the Belfast Trust. 
 A lower proportion of patients presenting in the Belfast and Northern Trusts were seen by a urologist within 4 weeks, 45% 
and 47% respectively, compared to 69%, 63% and 77% in the South Eastern, Southern and Western Trusts respectively. 
 Overall 28% of patients had their cancer diagnosed by TURB within 4 weeks of referral, while 61% waited 6 weeks or more. 
 A significantly higher proportion of patients in the Southern Trust (44%) had a cancer diagnosis within 4 weeks of referral 
compared to the other 4 Trusts (24%). 
 Patients who were referred to A&E (GP/self-referral) had the shortest duration from time of referral to TURB. 
 For patients on a red flag pathway the median time to TURB was 63 days. 13% had TURB within 4 weeks of referral, 32% 
within 6 weeks, while over two thirds waited more than 6 weeks. 
 Patients referred by GPs as routine, urgent/semi-urgent had the longest time from referral to TURB. 
Referral to Treatment 
 For patients with non-muscle invasive bladder cancer median time from first referral to secondary care to treatment (TURB) 
was 69 days with 41% of patients having first treatment within 62 days. 
 For patients with muscle invasive disease (T2 or higher) median time from first referral to secondary care to major surgery 
was 118 days and median time to curative-intent oncology was 171 days. 
Diagnosis to Treatment 
 42% of patients with muscle invasive disease had their major surgery within 62 days of diagnostic TURB. 
 Time to major surgery from TURB was greater than 90 days in one quarter of patients. 
 Median time from diagnostic TURB to treatment was 65 days for major surgery and 84 days for curative-intent oncology. 
 
COMMUNICATION WITH PRIMARY CARE AND PATIENT INFORMATION 
 Over 95% of patients had their diagnosis and management plan recorded in their GP letter. 
 Two thirds of GP letters mentioned that diagnosis was discussed with the patient and a third of letters that diagnosis had been 
discussed with their family. 
 In 31% of the letters, palliative care was mentioned. 
 Discussion of diagnosis and treatment plan was recorded in the clinical notes/CaPPS in just over 80% of patients.  
 
SURVIVAL 
 Risk of death from bladder cancer was higher for women 1.5:1.  However, when stage of disease was taken into account, this 
reduced to 1.3:1, or 30% higher in women. This however was no longer statistically significant.   
 The net survival decreased with age which means that older patients are more likely to die from their bladder cancer than 
younger patients, even when stage is taken into account. 
 2 years after diagnosis, men had 57% net survival while women had 47%. 
 Large differences in net survival at 2 years were present between the 3 stage groups: non-muscle invasive (88%), muscle 
invasive (47%), and locally advanced/metastatic disease (10%). 
 Those over 78 years at diagnosis had significantly poorer net survival (42%), than the younger age groups: 60% and 64% for 
age groups 0 to 69 and 70 to 77, respectively. 
 
RECOMMENDATIONS 
1. The public need to be educated about haematuria as an alarm symptom for cancer. 
2. Reasons for late and delayed presentation of bladder cancer should be investigated.  
3. Access to urology services should be assessed regionally. 
4. The pathways for bladder cancer investigation and treatment should be explored to speed up this process. 
5. Clinical Nurse Specialists should be available for all patients. 
6. Efforts to reduce the prevalence of smoking should continue as tobacco use is a risk factor. 
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This is a summary of a report on bladder cancers diagnosed in Northern Ireland during 2010 & 2011 
which can be found at www.qub.ac.uk/nicr 
 
AIMS 
1. To document care for bladder cancer patients in N. Ireland and compare with recommended guidance for 
investigation and treatment.  
2. To explore reasons for differences in bladder cancer survival in women compared to men. 
3. To serve as a benchmark for further audits. 
4. To make recommendations for service improvement. 
 
BACKGROUND 
The Bladder Bladder cancer 
The bladder is the organ that stores urine excreted by the 
kidneys before disposal by urination. It is a hollow muscular, 
elastic organ that sits on the pelvic floor. Urine enters the 
bladder via two ureters (from each of two kidneys) and exits 
via the urethra.  
The most common type of bladder cancer is known as 
transitional cell carcinoma (TCC). There exists also Carcinoma 
in situ (CIS) which is a flat, high-grade lesion in the 
epithelium. CIS does not invade past the bladder lining, but has 
a high risk of progression to invasive disease. 
Risk factors 
Tobacco smoking - causes 50-65% of male cases and 20-30% of female cases. Levels are associated with years of smoking and 
number of cigarettes smoked daily. An immediate decrease in risk occurs with cessation of smoking.  
Occupational exposure to chemicals (e.g. Dyes, paints, plastics) - second most important risk factor and accounts for 20-25% of 
all cases.  However, because of strict regulations these chemicals contribute minimally to the current levels of bladder cancer in 
Western countries. 
Bladder schistosomiasis (a parasitic disease) is associated with a five-fold increased risk of urinary bladder cancer. Infections 
with schistosomiasis affect about 600 million people in Africa, Asia, South America, and the Caribbean, but is not a risk-factor in 
N. Ireland.   
Other causes of bladder cancer include previous treatment for cancer – in particular, radiotherapy to the pelvis and some forms of 
chemotherapy. 
Common symptoms 
For early stage bladder cancer the most common symptom is blood in the urine (haematuria).  Late stage symptoms include 
haematuria, urgency, pain on passing urine (dysuria), increased frequency and pelvic pain.  In advanced disease, symptoms 
related to urinary tract obstruction, such as poor urine flow occur. 
 
INCIDENCE 2007-2011 
Transitional cell carcinoma (TCC) of the bladder: 
 8th most common cancer in men and 16th in women.  
 Accounted for 2.6% of all cancers (excluding non-melanoma skin cancer). 
 On average 154 men and 60 women diagnosed annually, this gender difference is probably due to lifestyle and occupation 
risk factors that differ between the sexes.  
Figure 1: Age distribution of patients diagnosed with bladder cancer in Northern Ireland 2007-2011 by sex, 
with age-specific rates 
  
 
 
 
 
   
          
          
          
          
          
          
   
 
INCIDENCE TRENDS 1993-2011 
Although, the numbers of people being diagnosed has remained relatively constant from 1993 to 2011, age-standardised rates 
have been falling by 1.7% (p<0.01) per year in men, and 1.3% (P=0.13) in women. This fall in age-standardised rates, while total 
numbers remains stable, reflects the ageing of the population. The faster-falling standardised-incidence rates in men possibly 
reflect changes in smoking-habits between the sexes.  Deaths show a similar pattern. 
 
INTERNATIONAL COMPARISONS 
Incidence: 1998-2007 
Incidence rates of bladder cancer in NI 
(male 11.8/100,000, female 
3.2/100,000 [world age-standardised 
rate]) during 1998-2002 were among 
the lowest in the Western World being 
significantly lower than most European 
countries, including the rest of the UK.  
 
By 2003-2007 rates in NI had 
increased to 18.3/100,000 and 
5.5/100,000 for males and females 
respectively, both of which were 
similar to the rates in England although 
they were still lower than those in 
Scotland and Denmark among others. 
(Fig. 2) 
 
Source: Cancer Incidence in Five 
Continents (CIV) 
Figure 2: International comparison of world age-standardised incidence 
rates for men and women diagnosed 2003-2007 (CIV – Volume X) 
Males Females 
  
 
Relative survival: 1995-2007 
The five-year (age-standardised) 
relative survival for bladder cancer 
patients diagnosed in 1995-1999 in NI 
was poor in comparison to the 
European average and England & 
Wales. The rate in men (65.0%) was 
comparable to Scotland, Slovenia, 
Poland, and France, but for women NI 
(54.6%) had the lowest rate among the 
EUROCARE-4 countries.  
 
The EUROCARE-5 data for patients 
diagnosed in 2000-2007 indicates that 
survival in NI was better than the 
European average for men and was 
similar to the average for women. 
However NI has a small number of 
female bladder cancers diagnosed each 
year, with the result that survival 
estimates fluctuate from year to year. 
(Fig. 3) 
 
Source: EUROCARE-4&5 
Figure 3: International comparison of age-standardised relative survival 
rates for men and women diagnosed 2000-2007 (EUROCARE-5) 
Males Females 
  
 
Impact of changing submitted codes 
Both Cancer Incidence in Five Continents IX and EUROCARE-4 included borderline pTa, pTis tumours in their definition of 
bladder cancer, but NICR submitted only invasive bladder cancer. However, for Cancer Incidence in Five Continents X and 
EUROCARE-5, NICR submitted both invasive bladder cancer and borderline pTa, pTis tumours. The result of changing the 
codes submitted was that incidence and patient survival increased; patients diagnosed with borderline tumours generally have 
better prognosis. 
 
  
 
 
SUMMARY OF RESULTS – DETAILS IN REPORT  
 
PRESENTATION, DIAGNOSIS AND STAGING 
 98% of bladder cancer patients diagnosed 2010 and 2011 were included in the audit (n=362 patients). 
 Half of patients were over 74 years and 73% were men. 
 72% were current or ex-smokers. 
 Macroscopic haematuria was the most common presenting symptom (80%). 
 58% of patients with symptom duration recorded had haematuria for at least 1 month and 12% over 6 months. 
 Women were more likely than men to present with abdominal pain, lethargy and weight loss, possibly reflecting later stage of 
disease at presentation. 
 57% of all patients were referred by their GPs (outpatients and A&E). 
 Overall 18% of patients were referred to outpatients by GPs as red flag suspect cancers and a further 14.6% were upgraded 
by consultants to a red flag pathway.  GP referrals to A&E accounted for 10.5% while11% were GP routine/urgent/semi-
urgent/ referrals to outpatients. 
 31% of patients referred to outpatients by GPs were upgraded to ‘red flag’ by consultants. 
 21% of patients presented via A&E. 
 Over a quarter of patients first presented to the Belfast Trust. 
 52% of patients first presented in outpatient clinics, with a further 16% first seen at a designated haematuria clinic. 
 86% of patients were first seen by urology. 
 73% of patients had seen a urologist within 42 days of referral, 39% within 2 weeks. 
 The duration from referral received to first seen by urologist was longer among patients who presented in the Belfast Trust. 
 90% of patients were discussed at MDM – Private patients were less likely to be discussed. 
 98% of patients had a cystoscopy; of these patients 98% had a TURB and 77% had a CT scan. 
 96% of patients with muscle invasive bladder cancer had a CT/MRI scan. 
 97% were histologically verified with 86% having transitional cell carcinoma. 
 98% of patients were staged, 45% Stage 1 and 26% Stage 4 at diagnosis. 
 
TREATMENT 
 95% of patients had a Trans Urethral Resection of Bladder -TURB. 
 A third of all TURBs were carried out in the Belfast Trust. 
 83 major surgical resections were performed: cystoprostatectomy (52), cystectomy (16), and anterior exenteration of pelvis 
(15). 
 The majority (93%) of radical cystectomies were performed in the Belfast City Hospital with 4 being performed in the 
Southern Trust, 1 in the Western Trust and 1 in the private sector. 
 89% of major surgical resections were performed by a uro-oncology surgeon with a case-load volume of 11 or more major 
procedures during the audit period. 
 11% were performed by urologists who performed 5 or fewer major procedures during the audit period. 
 83% of patients undergoing major surgery had lymph node resection performed. The median number of lymph nodes 
examined was 15 (range, 1-35) and the median number of positive nodes was 0 (range, 0-18). 
 37% of patients were recorded as having been seen by a Urology Clinical Nurse Specialist. This figure may be an 
underestimate as this data may not have been consistently available in the clinical notes or CaPPS. 
 Incidental prostate cancer was detected in 17/54 (32%) of men who had major surgical resection. 
 
Stage 1 
(Non-muscle invasive disease, n=161)  
 
 The majority of patients with non-
muscle invasive disease, or Stage 1, 
(86%, 139/161) had organ-conserving 
treatment with 11% (18/161) having 
radical cystectomy.  
 
 Just under two thirds (62%) received 
courses of intravesical chemotherapy 
and/or BCG therapy.  
 
 Just under a quarter had local tumour 
resection (TURB) with repeat 
cystoscopy to ensure disease 
eradication. 
 
Stage 2 & 3 
(Muscle invasive disease, n=100)  
 
 A third (36%) of patients with muscle 
invasive disease (Stage 2&3) had 
major surgical resection while 20% of 
patients had organ-conserving curative 
intent oncological therapy. A further 
16% had palliative oncological 
treatment. 
 In total 28% of patients with muscle 
invasive disease (Stage 2&3) had 
localised therapy only (TURB+/- 
intravesical therapy). Sixteen of these 
28 patients were deemed unfit due to 
advanced age and/or comorbidity, and 
a further 7 patients (25%) died within 3 
months of diagnosis. 
Stage 4 
(Advanced metastatic, n=94) 
 
 Just under one third (n=28) of patients 
with locally advanced/metastatic 
disease (Stage 4) had radical 
cystectomy with 6 patients having pre-
operative chemotherapy and 12 
patients requiring adjuvant palliative 
radiotherapy for residual/progressive 
disease following cystectomy.  
 
 One quarter (n=23) of patients were 
treated with palliative radiotherapy, 
while 26% of patients received 
supportive palliative care alone. 
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have been falling by 1.7% (p<0.01) per year in men, and 1.3% (P=0.13) in women. This fall in age-standardised rates, while total 
numbers remains stable, reflects the ageing of the population. The faster-falling standardised-incidence rates in men possibly 
reflect changes in smoking-habits between the sexes.  Deaths show a similar pattern. 
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Incidence rates of bladder cancer in NI 
(male 11.8/100,000, female 
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rate]) during 1998-2002 were among 
the lowest in the Western World being 
significantly lower than most European 
countries, including the rest of the UK.  
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increased to 18.3/100,000 and 
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Relative survival: 1995-2007 
The five-year (age-standardised) 
relative survival for bladder cancer 
patients diagnosed in 1995-1999 in NI 
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The EUROCARE-5 data for patients 
diagnosed in 2000-2007 indicates that 
survival in NI was better than the 
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 72% were current or ex-smokers. 
 Macroscopic haematuria was the most common presenting symptom (80%). 
 58% of patients with symptom duration recorded had haematuria for at least 1 month and 12% over 6 months. 
 Women were more likely than men to present with abdominal pain, lethargy and weight loss, possibly reflecting later stage of 
disease at presentation. 
 57% of all patients were referred by their GPs (outpatients and A&E). 
 Overall 18% of patients were referred to outpatients by GPs as red flag suspect cancers and a further 14.6% were upgraded 
by consultants to a red flag pathway.  GP referrals to A&E accounted for 10.5% while11% were GP routine/urgent/semi-
urgent/ referrals to outpatients. 
 31% of patients referred to outpatients by GPs were upgraded to ‘red flag’ by consultants. 
 21% of patients presented via A&E. 
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 52% of patients first presented in outpatient clinics, with a further 16% first seen at a designated haematuria clinic. 
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 The duration from referral received to first seen by urologist was longer among patients who presented in the Belfast Trust. 
 90% of patients were discussed at MDM – Private patients were less likely to be discussed. 
 98% of patients had a cystoscopy; of these patients 98% had a TURB and 77% had a CT scan. 
 96% of patients with muscle invasive bladder cancer had a CT/MRI scan. 
 97% were histologically verified with 86% having transitional cell carcinoma. 
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 A third of all TURBs were carried out in the Belfast Trust. 
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   TIMELINES: REFERRAL TO DIAGNOSIS AND TREATMENT 
Referral to First Seen by Urologist and TURB 
 59% of patients were seen by a urologist within 4 weeks of referral while 27% waited over 6 weeks. 
 The overall duration from referral received to first seen by urologist was longer for patients presenting in the Belfast Trust. 
 A lower proportion of patients presenting in the Belfast and Northern Trusts were seen by a urologist within 4 weeks, 45% 
and 47% respectively, compared to 69%, 63% and 77% in the South Eastern, Southern and Western Trusts respectively. 
 Overall 28% of patients had their cancer diagnosed by TURB within 4 weeks of referral, while 61% waited 6 weeks or more. 
 A significantly higher proportion of patients in the Southern Trust (44%) had a cancer diagnosis within 4 weeks of referral 
compared to the other 4 Trusts (24%). 
 Patients who were referred to A&E (GP/self-referral) had the shortest duration from time of referral to TURB. 
 For patients on a red flag pathway the median time to TURB was 63 days. 13% had TURB within 4 weeks of referral, 32% 
within 6 weeks, while over two thirds waited more than 6 weeks. 
 Patients referred by GPs as routine, urgent/semi-urgent had the longest time from referral to TURB. 
Referral to Treatment 
 For patients with non-muscle invasive bladder cancer median time from first referral to secondary care to treatment (TURB) 
was 69 days with 41% of patients having first treatment within 62 days. 
 For patients with muscle invasive disease (T2 or higher) median time from first referral to secondary care to major surgery 
was 118 days and median time to curative-intent oncology was 171 days. 
Diagnosis to Treatment 
 42% of patients with muscle invasive disease had their major surgery within 62 days of diagnostic TURB. 
 Time to major surgery from TURB was greater than 90 days in one quarter of patients. 
 Median time from diagnostic TURB to treatment was 65 days for major surgery and 84 days for curative-intent oncology. 
 
COMMUNICATION WITH PRIMARY CARE AND PATIENT INFORMATION 
 Over 95% of patients had their diagnosis and management plan recorded in their GP letter. 
 Two thirds of GP letters mentioned that diagnosis was discussed with the patient and a third of letters that diagnosis had been 
discussed with their family. 
 In 31% of the letters, palliative care was mentioned. 
 Discussion of diagnosis and treatment plan was recorded in the clinical notes/CaPPS in just over 80% of patients.  
 
SURVIVAL 
 Risk of death from bladder cancer was higher for women 1.5:1.  However, when stage of disease was taken into account, this 
reduced to 1.3:1, or 30% higher in women. This however was no longer statistically significant.   
 The net survival decreased with age which means that older patients are more likely to die from their bladder cancer than 
younger patients, even when stage is taken into account. 
 2 years after diagnosis, men had 57% net survival while women had 47%. 
 Large differences in net survival at 2 years were present between the 3 stage groups: non-muscle invasive (88%), muscle 
invasive (47%), and locally advanced/metastatic disease (10%). 
 Those over 78 years at diagnosis had significantly poorer net survival (42%), than the younger age groups: 60% and 64% for 
age groups 0 to 69 and 70 to 77, respectively. 
 
RECOMMENDATIONS 
1. The public need to be educated about haematuria as an alarm symptom for cancer. 
2. Reasons for late and delayed presentation of bladder cancer should be investigated.  
3. Access to urology services should be assessed regionally. 
4. The pathways for bladder cancer investigation and treatment should be explored to speed up this process. 
5. Clinical Nurse Specialists should be available for all patients. 
6. Efforts to reduce the prevalence of smoking should continue as tobacco use is a risk factor. 
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This is a summary of a report on bladder cancers diagnosed in Northern Ireland during 2010 & 2011 
which can be found at www.qub.ac.uk/nicr 
 
AIMS 
1. To document care for bladder cancer patients in N. Ireland and compare with recommended guidance for 
investigation and treatment.  
2. To explore reasons for differences in bladder cancer survival in women compared to men. 
3. To serve as a benchmark for further audits. 
4. To make recommendations for service improvement. 
 
BACKGROUND 
The Bladder Bladder cancer 
The bladder is the organ that stores urine excreted by the 
kidneys before disposal by urination. It is a hollow muscular, 
elastic organ that sits on the pelvic floor. Urine enters the 
bladder via two ureters (from each of two kidneys) and exits 
via the urethra.  
The most common type of bladder cancer is known as 
transitional cell carcinoma (TCC). There exists also Carcinoma 
in situ (CIS) which is a flat, high-grade lesion in the 
epithelium. CIS does not invade past the bladder lining, but has 
a high risk of progression to invasive disease. 
Risk factors 
Tobacco smoking - causes 50-65% of male cases and 20-30% of female cases. Levels are associated with years of smoking and 
number of cigarettes smoked daily. An immediate decrease in risk occurs with cessation of smoking.  
Occupational exposure to chemicals (e.g. Dyes, paints, plastics) - second most important risk factor and accounts for 20-25% of 
all cases.  However, because of strict regulations these chemicals contribute minimally to the current levels of bladder cancer in 
Western countries. 
Bladder schistosomiasis (a parasitic disease) is associated with a five-fold increased risk of urinary bladder cancer. Infections 
with schistosomiasis affect about 600 million people in Africa, Asia, South America, and the Caribbean, but is not a risk-factor in 
N. Ireland.   
Other causes of bladder cancer include previous treatment for cancer – in particular, radiotherapy to the pelvis and some forms of 
chemotherapy. 
Common symptoms 
For early stage bladder cancer the most common symptom is blood in the urine (haematuria).  Late stage symptoms include 
haematuria, urgency, pain on passing urine (dysuria), increased frequency and pelvic pain.  In advanced disease, symptoms 
related to urinary tract obstruction, such as poor urine flow occur. 
 
INCIDENCE 2007-2011 
Transitional cell carcinoma (TCC) of the bladder: 
 8th most common cancer in men and 16th in women.  
 Accounted for 2.6% of all cancers (excluding non-melanoma skin cancer). 
 On average 154 men and 60 women diagnosed annually, this gender difference is probably due to lifestyle and occupation 
risk factors that differ between the sexes.  
Figure 1: Age distribution of patients diagnosed with bladder cancer in Northern Ireland 2007-2011 by sex, 
with age-specific rates 
  
 
 
 
 
   
          
          
          
